Background: Despite progress achieved with new chemotherapeutic and endocrine agents, advanced breast cancer (ABC) remains a disease with poor prognosis. We sought to determine the efficacy of gemcitabine (GC) and oral vinorelbine (VB) in heavily preatreated ABC.
Patients And Methods: Patients previously treated with anthracyclines and taxanes in the metastatic setting with progressive disease were eligible. Treatment consisted of VB (60 mg/m2, orally) and GC (1000 mg/m2, intravenous infusion), every two weeks of a 28- day cycle.
Results: Thirty-one patients with ABC were enrolled. Toxicity was acceptable, mainly haematological. Three and 8 patients achieved a complete (9.6%) and partial (25.8%) response, respectively; ten patients (32.2%) had stable disease. Median time-to-progression was 5.3 months, while in responders 8.6 months. Median overall survival was 14 months.
Conclusion: Oral VB and GC is an active and well-tolerated combination in anthracycline/taxane-pretreated ABC, representing an interesting option in this poor prognosis group of patients.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
PLGA-Nano-Encapsulated Disulfiram Inhibits Cancer Stem Cells and Targets Non-Small Cell Lung Cancer In Vitro and In Vivo.
Biomolecules
December 2024
Faculty of Science and Engineering, University of Wolverhampton, Wolverhampton WV1 1LY, UK.
Cancer stem cells (CSCs) play a key role in non-small cell lung cancer (NSCLC) chemoresistance and metastasis. In this study, we used two NSCLC cell lines to investigate the regulating effect of hypoxia in the induction and maintenance of CSC traits. Our study demonstrated hypoxia-induced stemness and chemoresistance at levels comparable to those in typical CSC sphere culture.
View Article and Find Full Text PDFDevelopment and optimization of a high-throughput HPLC-MS/MS method for the simultaneous determination of Cedazuridine, Gemcitabine and its metabolite in mouse plasma.
J Chromatogr B Analyt Technol Biomed Life Sci
December 2024
Department of Pharmaceutical Analysis, Wuya College of Innovation, Shenyang Pharmaceutical University, No. 103, Wenhua Road, Shenyang 110016, China. Electronic address:
Article Synopsis
- Gemcitabine (GEM) is widely used to treat solid tumors, but its effectiveness is limited by rapid metabolism into an inactive form (dFdU) by the enzyme cytidine deaminase (CDA), which decreases its oral bioavailability.
- Cedazuridine (CDZ) has been identified as a potent inhibitor of CDA, and when combined with GEM, it may enhance GEM's oral bioavailability.
- A study using HPLC-MS/MS confirmed that CDZ significantly improved GEM's bioavailability in mice by inhibiting its metabolism, suggesting potential benefits for clinical applications of the GEM-CDZ combination.
Phase I Trial of Upamostat Combined With Gemcitabine in Locally Unresectable or Metastatic Pancreatic Cancer: Safety and Preliminary Efficacy Assessment.
Cancer Med
January 2025
Department of Medical Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
Aim: This study aimed to determine the maximum tolerated dose (MTD) of the urokinase plasminogen activator (uPA) inhibitor upamostat (LH011) in combination with gemcitabine for locally advanced unresectable or metastatic pancreatic cancer.
Method: Seventeen patients were enrolled and received escalating doses of oral LH011 (100, 200, 400, or 600 mg) daily alongside 1000 mg/m of gemcitabine. Safety profiles, tumor response (including response rate and progression-free survival), pharmacokinetics, and changes in CA199 and D-dimer levels were assessed.
A non-inferiority, phase III trial of gemcitabine plus capecitabine gemcitabine plus carboplatin as first-line therapy and tumor-infiltrating lymphocytes as a prognostic biomarker in patients with advanced triple-negative breast cancer.
Ther Adv Med Oncol
December 2024
Department of Breast Oncology, Key Laboratory of Breast Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, West Huan-Hu Road, Ti Yuan Bei, Hexi District, Tianjin 300060, China.
Article Synopsis
- A clinical trial compared the effectiveness and safety of gemcitabine plus capecitabine (GX) versus gemcitabine plus carboplatin (GC) in treating advanced triple-negative breast cancer (TNBC) patients.
- The results showed that while median progression-free survival (PFS) was similar, the GC regimen was more effective, particularly in patients with high tumor-infiltrating lymphocytes (TILs).
- The GX regimen is still considered for patients who might struggle with the side effects associated with the GC treatment, particularly hematological toxicity.
Pembrolizumab (MK-3475) plus platinum and gemcitabine as first-line treatment of recurrent/metastatic head and neck squamous cell carcinoma (PIPER): a phase 2, multicentre, single-arm protocol study in Malaysia.
BMJ Open
December 2024
Clinical Oncology Unit, Faculty of Medicine, University of Malaya, Kuala Lumpur, Wilayah Persekutuan, Malaysia
Article Synopsis
- The study aims to evaluate the effectiveness of combining pembrolizumab with platinum and gemcitabine (PG) as a first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) in Malaysia, comparing it to the existing treatment with pembrolizumab plus platinum and 5-fluorouracil (PF).
- It is a phase 2, open-label, multicenter study enrolling up to 89 participants, where pembrolizumab will be administered alongside chemotherapy for six cycles, and various response and safety metrics will be assessed.
- The trial has received ethical approval and its results will be shared through conferences and scientific publications, aiming to contribute valuable findings to cancer treatment discussions.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!